Company Profile

Print
Homepage  >  MEDTOX Info  >  Investors  >  Company Profile

MEDTOX Scientific, Inc. is engaged throughout the United States in two distinct, but related businesses - forensic and clinical laboratory services to corporations, pharmaceutical companies and health care organizations (the Laboratory segment), and the manufacturing and distribution of diagnostic drug screening devices (the Diagnostic segment). MEDTOX Laboratories, Inc., is the Laboratory segment located in St. Paul, MN, and is the nation's third largest SAMHSA-certified drug testing laboratory. It operates an extensive CAP-accredited clinical and occupational testing laboratory.  MEDTOX has developed over 900 individual assays for use in bio-analytical studies for the pharmaceutical industry. MEDTOX Laboratories can provide pharmaceutical sponsors all required services for their Phase 1 - Phase 4 clinical trials. Through MEDTOX Diagnostics, Inc. (the Diagnostic segment) in Burlington, NC, MEDTOX manufactures 20 FDA-cleared diagnostic drug screening devices for use in corporate, corrections, rehabilitation and clinical trial programs.

MEDTOX Scientific, Inc.  Investor Relations 877-715-7236

Basic Industries:  Lab & POC Diagnostic Drug Testing, Clinical Trials, Clinical Toxicology, Lead Screening, Lab Services

MEDTOX Focus:  Building a Business within Laboratory and Diagnostic Testing Markets

NASDAQ Symbol:  MTOX

NASDAQ Fundamentals


Vital Statistics - Year-End 2009
2009 Revenue: $84.1 Million
2009 EPS: $0.15
Shares Outstanding: 8,572,079
Approximate Public Float: 7,430,000
Insider Ownership: 14%
Institutional Ownership: 64%
Fiscal Year End: December 31

NEWS & INSIGHTS

View UPS Shipping Detail

Attention Clients:  Important change in implementation date for revisions to HHS and DOT workplace drug testing programs.

SAMHSA has postponed the May 1, 2010 implementation of the revised HHS Mandatory Guidelines for Federal Workplace Drug Testing Programs.  The new effective date is October 1, 2010.

The delay was issued to provide sufficient time for the DOT to evaluate comments and issue a final rule harmonizing its regulations with the revised HHS Guidelines in a time frame that will permit implementation of the rules at the same time.  This action is welcomed; it will allow HHS-certified laboratories to use the same testing and reporting procedures for Federal workplace and transportation workplace drug testing programs subject to DOT Regulations, avoid the confusion of administering regulatory programs with different requirements and will ensure fairness in treatment of employees subject to the rules.  

A notice is posted in the Federal Register for publication on April 30, 2010.  The document is available at the Federal Register’s website:  Click Here

Workplace Drug Testing Updates

© 2008 MEDTOX Scientific, Inc. All rights reserved.